Commission Implementing Regulation (EU) 2022/20 of 7 January 2022 laying down rules for the application of Regulation (EU) No 536/2014 of the European Parliament and of the Council as regards setting up the rules and procedures for the cooperation of the Member States in safety assessment of clinical trials (Text with EEA relevance)
Article 8Recommendations of corrective measures and other actions for safety oversight related to the active substance
In force · version of Jan 30, 2022
1.If the safety assessing Member State identifies safety concerns related to the active substance from sources other than the screening and assessment referred to in Articles 6 and 7, it may submit recommendations for corrective measures and other risk mitigating actions for safety oversight to the reporting Member States and Member States concerned.
2.Following a recommendation pursuant to Article 6(7), Article 7(1), point (d), or paragraph 1 of this Article, the reporting Member States of the clinical trials in which the active substance is used should coordinate the action to be taken for these clinical trials with the Member States concerned.
3.Member States concerned may at any time take corrective measures and other actions for safety oversight related to the active substance in their territory in accordance with Article 77 of Regulation (EU) No 536/2014.